Neumora Therapeutics (NMRA) Q3 2024 earnings summary

Executive summary

• Advanced seven clinical and preclinical neuroscience programs targeting neuropsychiatric and neurodegenerative diseases, with a focus on significant unmet needs and precision medicine approaches.

• Lead asset navacaprant is in three Phase 3 trials for major depressive disorder (MDD), with additional studies in bipolar depression and Alzheimer's agitation ongoing.

• No products approved or revenue from product sales; significant net losses since inception, driven by R&D and acquired in-process R&D costs.

• Pipeline includes M4 muscarinic positive allosteric modulators (PAMs) and other assets for conditions such as schizophrenia, Parkinson's, and ALS.

• Completed IPO in September 2023, raising $226.5 million; strong cash position of $341.3 million as of September 30, 2024, expected to fund operations into mid-2026.

Financial highlights

• Total operating expenses for Q3 2024 were $76.6 million, up from $56.9 million in Q3 2023, primarily due to increased R&D activity for Phase 3 programs and business growth investments.

• Net loss of $72.5 million for Q3 2024, compared to $53.0 million in Q3 2023; net loss of $185.0 million for the nine months ended September 30, 2024.

• R&D expenses rose to $60.6 million in Q3 2024 from $41.6 million in Q3 2023; G&A expenses increased to $16.0 million in Q3 2024.

• Cash, cash equivalents, and marketable securities totaled $341.3 million as of September 30, 2024.

• Net loss per share was $0.45 (basic and diluted) for Q3 2024, with 159.6 million weighted-average shares outstanding.

Outlook and guidance

• Topline results from KOASTAL-1 Phase 3 study for navacaprant in MDD expected by year-end 2024; KOASTAL-2 and -3 results in H1 2025.

• Bipolar depression and Alzheimer's agitation study data expected in H2 2025.

• Five clinical catalysts expected over the next 18 months, including Phase 3 and Phase 2 data for navacaprant and Phase 1b data for NMRA-511.

• IND submission for next M4 PAM program planned for H1 2025.

• Cash runway projected to support operations into mid-2026.